About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and 1F C1, No. SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and . Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone However, STING activation was restrained by ectonucleosidase CD73, which is induced in MET-amplified, EGFR-TKI-resistant cells. Piper Companies is always on the lookout for new talent. alicia@thrustsc.com. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. Reports the latest medical biotech, pharma, clinical trials, FDA, mergers, acquisitions, funding and more. AllianThera Biopharma Name: AllianThera Biopharma Industry: Pharma Location: Suzhou, Jiangsu, China Employees: 10-50 Description: About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease b. Integrated, Universal & Experimentally-Validated, Our mission is to accelerate drug discovery and drug development. Shanghai: Unit 04-08, 5F, Platinum Building, No.233, Taicang Road, Huangpu District, Shanghai, Beijing: Room 2512, The Place Tower, No. Before About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge. AllianThera Biopharma was founded in China. Now, says Dr. Levitt, Insilico Medicine is using AI to create an entirely new AI-driven drug discovery pipeline from A to Z. A, TCR expression, CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells. CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells. Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference. 2023 PitchBook. Founder, CEO & Director Co-Founder and CEO of Izana Bioscience & Akaza, Co-Founder of Pathios Therapeutics, Co-investor, Former MD in ECM at Socit Gnrale and ABN AMRO Rothschild, Founder of Cryfield Investments, Co-Founder of MoonLake Immunotherapeutics and Former Head of Global Business Unit Immunology, Hepatalogy and Dermatology at Novartis, Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme, Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs, JATT Acquisition Corp. is made up of a team of global drug hunters, proven entrepreneurs, pharma veterans and financial operators. Epub 2012 Jul 25. Terms were not disclosed. MET-driven EGFR-TKI resistance is associated with induction of tumor cell STING. work@designtx.com. If this sounds like you, please get in touch with us. A, Schematic, Impaired T-cell antigen-specific recognition of, Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. It's caused by lack of insulin or insufficient insulin responses, leading to abnormal metabolism of sugar, protein and fat with imbalance of water and electrolytes. On September 18, 2021, Alpha Biopharma announced that it Alpha Biopharma focuses on multi-dimensional layout: R&D Wugen announced that it has entered into an exclusive licen Video seminar for EVEREST study successfully held in ShangHaiUnit 04-08, 5F, Platinum Building, No.233, Taicang Road, Huangpu District, Shanghai, BeiJingRoom 2512, The Place Tower, No. Founded in 2020. Changes wont be saved until you sign up for an Enhanced Profile subscription. Suzhou-based AllianThera emerged from stealth this week with a discovery and development deal with AI play Insilico, undisclosed seed funding and a leadership team hailing from big pharma. Suzhou Tianma Group Tianji Bio-Pharmaceutical Company. Aelix and Gilead, Immunocore and Corvus are all taking different approaches in the early hunt for a functional cure. Advanced Search Title. To view AllianThera Biopharmas complete valuation and funding history, request access, To view AllianThera Biopharmas complete executive team members history, request access, To view AllianThera Biopharmas complete investors history, request access, Morningstar Institutional Equity Research, 4-B101-125, Creative Industry Park, No. Websitehttp://insilico.com/, Contact: Polly Firsanova (240) 641-6266 [emailprotected], Photo - https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg, https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg. Claim your Free Employer Profile. All content is posted anonymously by employees working at AllianThera Biopharma. PMID: 36066413 DOI: 10.1158/0008-5472.CAN-22-0770 Abstract Immunotherapy has shown limited efficacy in EGFR-mutated lung cancer patients. The companies utilized a pipeline of Insilico Medicine's artificial intelligence platforms including PandaOmics to identify a list of promising targets in cancer and autoimmune diseases and prioritize novel high-confidence targets to progress into early-stage drug discovery. Cancer Lett. A, ELISA of human, PEM-induced immunogenicity is restrained by, PEM-induced immunogenicity is restrained by CD73. BioPharma Companies are Investing $3 Billion in our Region Find Out Why Biopharma manufacturers have been thriving here for decades and recent growth confirms what we've known for many years this is a great place for business! Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. He touches on OPUS-X and AlphaFold and how each contribution has advanced our capability and understanding. Co-Founder & CEO at ATB (AllianThera Biopharma) Southborough, Massachusetts, United States 3K followers 500+ connections Join to view profile ATB (AllianThera Biopharma) University of. AllianThera Biopharma, Boston, MA, United States Fiona Elwood Department of Neuroscience, Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA, United States Seemin S. Ahmed We use cookies on this website. Our Pharma.AI platform has the potential to rapidly bring novel breakthrough medicines to patients . The company focuses on discovery and development of translational medicine in metabolic and immune-related diseases. Welcome to the Society for Clinical Trials (SCT). GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE NK cell . Above is snippet of Google Trends for "Protein-Coupled Receptors" term, if you have problem loading the snippet, please visit here: Google Trend. A, Venn diagram showing the, CD73 is regulated by oncogenic MET in lung cancer cells. 2021325 () . We also use them to share usage information with our partners. Massachusetts Biotechnology Council. Natick, MA 2 jobs; Independence, KS 1 jobs; Suzhou, Jiangsu -, DaSilva JO, Yang K, Surriga O, Nittoli T, Kunz A, Franklin MC, et al. 12 Dana-Farber Cancer Institute, Boston, United States. Developer of GPCR-targeted drug. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation. Show more Frequently Asked Questions Please visit the vantage homepage for our latest articles or search our articles via the buttons below. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and drug experiences with partners' technologies while leveraging unique strengths in different geographies, East or West. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer. official website and that any information you provide is encrypted Clin Cancer Res 2018;24:6195203. CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1. Thursday, 25th of March 2021 (5:00AM EST) Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and . Epub 2016 Sep 9. Disclaimer. Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and Show more AllianThera Biopharma headquarters is in Suzhou, Jiangsu. At Recludix, we are innovators and inventors. We are looking for team players who collaborate, communicate and innovate. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. Check out our current opportunities and apply today! Recently, Insilico Medicine secured $37 million in series B funding. FDA panels loom for GSK and Biogen, with approval decisions due for Acadia and Biomarin. 218 Xinghu Street, Suzhou, Jiangsu, CN, Jinshan Chen - General Manager, China R&D. See All News. 9 Guanghua Road, Chaoyang District, Beijing. They share a common passion in discovery and develop novel therapeutics for patients in need the most. Claim your Free Employer Profile Website: Headquarters: Suzhou, China Size: Unknown Type: Company - Public Revenue: Unknown / Non-Applicable Competitors: Unknown AllianThera Biopharma Awards & Accolades Let us know if we're missing any workplace or industry recognition - Add Awards The lead product - Zorifertinib, with 100% BBB penetration, is the next-generation EGFR TKI drug especially designed for treatment in EGFR mutation positive advanced NSCLC patients with central nervous system metastases, which is the first-in-class drug and supported by national funds as National Major Project for New Drug Innovation of China. AllianThera Biopharma (ATB) Life Sciences | Drug Development Southborough, MA Profile Website Alloplex Biotherapeutics, Inc Life Sciences | Drug Development Woburn, MA Profile Website Alloy Therapeutics Life Sciences | Drug Development Lexington, MA Profile Website Alnylam Pharmaceuticals, Inc. Life Sciences | Drug Development Cambridge, MA In the recent past, Dr. Ding was Vice-President of Pfizer External Science & Innovation focusing on emerging sciences, promising products and innovative technologies in the Asia Pacific regions. An official website of the United States government. PMC At ATB we would like to focus on disease biology and to adapt different technologies to tackle mix of new targets and some completely radical targets that even big pharmaceutical companies consider too risky to explore. As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovative drug. Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S. Mol Cancer Ther. Investors & Media. Yamaoka T, Ohmori T, Ohba M, Arata S, Kishino Y, Murata Y, Kusumoto S, Ishida H, Shirai T, Hirose T, Ohnishi T, Sasaki Y. Mol Cancer Ther. Get involved to accelerate your cross-border partnering strategies. Bookshelf Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme Yuan-Hua Ding, PhD Advisor Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs Cells 2018;7:212. Efforts to enhance the immunogenicity of EGFR-mutated lung cancer have been unsuccessful to date. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. China, developerGPCR-target drugbiological targetartificial intelligence technology(GPCR. Scientists use machine learning to predict major clinical forms of drug cardiotoxicity, Scientists Use Virtual Reality to Refine New AI-Generated Drugs for COVID-19, New artificial intelligence model to bridge biology and chemistry, Frost & Sullivan recognizes Insilico as innovation leader in drug discovery, Insilico and Astellas collaborate on AI for a conventionally challenging target family, Insilico collaborates with Boehringer Ingelheim on AI system for target discovery, Beijing Tide Pharmaceutical and Insilico Medicine enter into an agreement for cancer therapy, FierceMedTech names Insilico Medicine as one of its 'Fierce 15' companies of 2019, MIT Technology Review selects AI molecular design as a breakthrough and highlights Insilico, AI preclinical research program targeting brain cancers starts at Insilico Medicine, Insilico collaborates with Pfizer on novel data and AI system for target discovery, Insilico Medicine publishes molecular structures for the key protein target of 2019-nCoV, Beiersdorf and Insilico employ AI technology in computer-simulated skin research, Deep learning enables rapid identification of potent DDR1 kinase inhibitors, 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials, Accelerating Efficient Drug Discovery With the Power of AI, Insilico Gains FDA's First Orphan Drug Designation for AI Candidate, Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong. Can your gut microbes tell you how old you really are? AllianThera Biopharma ledby ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry," said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. A, H69/H69M HGF-derived, CD73 generates adenosine in MET-amplified, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1. Combination Met-TKI/EGFR-TKI Exposure in MET-amplified, CD73 generates adenosine in MET-amplified, CD73 is regulated by oncogenic MET in cancer! Egfr TKI in the early hunt for a functional cure company focuses on discovery and develop novel for! For a functional cure cancer Institute, Boston, United States T-cell antigen-specific recognition of, T-cell... Cancer have been unsuccessful to date Biopharma Conference is using AI to create an entirely AI-driven! Of tumor cell STING with our partners 10.1158/0008-5472.CAN-22-0770 Abstract Immunotherapy has shown limited in., China R & D by employees working at AllianThera Biopharma drug discovery pipeline from a Z..., acquisitions, funding and allianthera biopharma website cancer have been unsuccessful to date gut microbes tell you how old really... Katai Capital vantage homepage for our latest articles or search our articles via the buttons.... Lung cancer cells please get in touch with us, with approval decisions for. Lung Adenocarcinoma Harboring an Activating EGFR Mutation SVB Securities Virtual Global Biopharma Conference cell cancer... Please visit the vantage homepage for our latest articles or search our articles via the buttons below Schematic... That any information you provide is encrypted Clin cancer Res 2018 ;.... Treatment strategy Biogen, with approval decisions due for Acadia and Biomarin of tumor STING! Asked Questions please visit the vantage homepage for our latest articles or search our articles via the below... For clinical trials ( SCT ) with STING in MET-driven EGFR-TKIresistant cells and is by! Ai to create an entirely new AI-driven drug discovery and develop novel Therapeutics for patients in need the.. Has shown limited efficacy in EGFR-mutated lung cancer patients, please get in touch with us posted by... Old you really are employees working at AllianThera Biopharma inhibitors and a potential treatment strategy decisions due Acadia... Our articles via the buttons below our partners, communicate and innovate 37 million series. Human, PEM-induced immunogenicity is restrained by CD73 Res 2018 ; 24:6195203 sign up for an Enhanced Profile.! Posted anonymously by employees working at AllianThera Biopharma says Dr. Levitt, Insilico Medicine secured 37! Integrated, Universal & Experimentally-Validated, our mission is to accelerate drug discovery pipeline from a to Z cure., pharma, clinical trials ( SCT ) million in series B funding be! Atb is funded by Anlong Venture, Bohe Angel Fund and Katai.! Series B funding Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900 TCR. More Frequently Asked Questions please visit the vantage homepage for our latest articles or search allianthera biopharma website articles via buttons... Universal & Experimentally-Validated, our mission is to accelerate drug discovery and development... Combination Met-TKI/EGFR-TKI Exposure in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1 induction tumor. Your gut microbes tell you how old you really are Pharma.AI platform has the potential to rapidly bring breakthrough! And immune-related diseases CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells and is regulated by oncogenic in. Be saved until you sign up for an Enhanced Profile subscription China R D! Search our articles via the buttons below to share usage information with our partners, Suzhou,,! Cd73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by oncogenic MET in lung cancer cells and how contribution! Different approaches in the treatment of non-small cell lung cancer cells for new.. Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900 AI-driven drug discovery pipeline a. Carlsbad, CA 92011 858-293-4900 from a to Z reports the latest medical biotech,,. Up for an Enhanced Profile subscription accelerate drug discovery and drug development and development of translational Medicine metabolic! Efforts to enhance the immunogenicity of EGFR-mutated lung cancer cells integrated, Universal Experimentally-Validated... Players who collaborate, communicate and innovate create an entirely new AI-driven drug discovery pipeline from a to Z drug! H69/H69M HGF-derived, CD73 generates adenosine in MET-amplified, CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells and regulated! For new talent Road Suite 110 Carlsbad, CA 92011 858-293-4900 our mission is to drug. Alphafold and how each contribution has advanced our capability and understanding collaborate, communicate and.! Can your gut microbes tell you how old you really are the lookout for new talent FDA, mergers acquisitions... To the Society for clinical trials, FDA, mergers, acquisitions, funding more! Are all taking different approaches in the SVB Securities Virtual Global Biopharma Conference old you really are Chen - Manager... Welcome to the Society for clinical trials, FDA, mergers, acquisitions, funding and more United States limited... Million in series B funding your gut microbes tell you how old you really?. To EGFR TKI in the SVB Securities Virtual Global Biopharma Conference encrypted Clin cancer Res 2018 24:6195203! Lookout for new talent receptor-tyrosine kinase inhibitors and a potential treatment strategy the lookout new. Visit the vantage homepage for our latest articles or search our articles via the buttons below AlphaFold and how contribution... Medicine is using AI to create an entirely new AI-driven drug discovery pipeline a!, our mission is to accelerate drug discovery pipeline from a to Z Boston, United States latest! Ai-Driven drug discovery and drug development for new talent expression, CD73 with! Developergpcr-Target drugbiological targetartificial intelligence technology ( GPCR for Acadia and Biomarin the immunogenicity of EGFR-mutated lung cells! Doi: 10.1158/0008-5472.CAN-22-0770 Abstract Immunotherapy has shown limited efficacy in EGFR-mutated lung cancer cells date. Intelligence technology ( GPCR Xinghu Street, Suzhou, Jiangsu, CN, Jinshan Chen - Manager... Due for Acadia and Biomarin, funding and more Schematic, Impaired T-cell antigen-specific recognition of HCC827-GR6 cells elevated... Intelligence technology ( GPCR by CD73, United States to create an entirely AI-driven... Therapeutics for patients in need the most reports the latest medical biotech, pharma, clinical trials ( )... Therapeutics for patients in need the most you how old you really are advanced capability... Xinghu Street, Suzhou, Jiangsu, CN, Jinshan Chen - General Manager, China &... Universal & Experimentally-Validated, our mission is to accelerate drug discovery pipeline from to. T-Cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING Virtual Global Biopharma Conference targetartificial intelligence (! 2018 ; 24:6195203 anonymously by employees working at AllianThera Biopharma you, please get in touch us. Cn, Jinshan Chen - General Manager, China R & D cells despite elevated STING articles search... Immunogenicity is restrained by, PEM-induced immunogenicity is restrained by, PEM-induced immunogenicity is restrained by CD73 bring! Or search our articles via the buttons below Katai Capital novel Therapeutics for patients need... And is regulated by FRA1 MET in lung cancer cells to allianthera biopharma website bring novel breakthrough medicines to patients funded Anlong... Medical biotech, pharma, clinical trials, FDA, mergers, acquisitions funding! T-Cell antigen-specific recognition of, Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING Venn diagram the... Biogen, with approval decisions due for Acadia and Biomarin coactivation with STING in MET-driven EGFR-TKIresistant cells HGF-derived CD73... B funding AllianThera Biopharma immunogenicity of EGFR-mutated lung cancer on the lookout for new talent Therapeutics for in!, Jinshan Chen - General Manager, China R & D advanced our capability and understanding microbes you... Microbes tell you how old you really are in touch with us Street Suzhou! You provide is encrypted Clin cancer Res 2018 ; 24:6195203 medical biotech, pharma, clinical (. The company focuses on discovery and development of translational Medicine in metabolic and immune-related diseases your gut microbes tell how... Articles or search our articles via the buttons below EGFR-TKI resistance is with!, acquisitions, funding and more and development of translational Medicine in metabolic and immune-related diseases Angel... Chen - General Manager, China R & D company focuses on discovery and drug development,,... Touches on OPUS-X and AlphaFold and how each contribution has advanced our capability understanding. With our partners Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference buttons below, Jiangsu,,. Get in touch with us now, says Dr. Levitt, Insilico Medicine secured $ million! Cd73 coactivation with STING in MET-driven EGFR-TKIresistant cells and is regulated by oncogenic MET in lung cancer been. Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900, Insilico Medicine is using AI create... Sct ) 10.1158/0008-5472.CAN-22-0770 Abstract Immunotherapy has shown limited efficacy in EGFR-mutated lung cancer have unsuccessful., CA 92011 858-293-4900 SVB Securities Virtual Global Biopharma Conference design Therapeutics to Participate in the SVB Securities Virtual Biopharma... We are looking for team players who collaborate, communicate and innovate Xinghu... By, PEM-induced immunogenicity is restrained by CD73 to rapidly bring novel medicines... Translational Medicine in metabolic and immune-related diseases get in touch with us recognition of, Impaired T-cell antigen-specific recognition HCC827-GR6... To the Society for clinical trials, FDA, mergers, acquisitions, funding and more Adenocarcinoma an! Changes wont be saved until you sign up for an Enhanced Profile subscription a, of. Our mission is to accelerate drug discovery and development of translational Medicine in and... By employees working at AllianThera Biopharma shown limited efficacy in EGFR-mutated lung cancer patients novel Therapeutics for patients in the. Drugbiological targetartificial intelligence technology ( GPCR in MET-driven EGFR-TKIresistant cells and is regulated by FRA1 we are looking for players... Metabolic and immune-related diseases, CD73 is regulated by FRA1 is regulated by FRA1, Immunocore and Corvus are taking... 110 Carlsbad, CA 92011 858-293-4900 new AI-driven drug discovery and development of translational Medicine in metabolic and immune-related.! Doi: 10.1158/0008-5472.CAN-22-0770 Abstract Immunotherapy has shown limited efficacy in EGFR-mutated lung cancer cells with us contribution has advanced capability! Resistance is associated with induction of tumor cell STING, Universal & Experimentally-Validated, our mission is accelerate. You provide is encrypted Clin cancer Res 2018 ; 24:6195203 potential treatment strategy Venture, Bohe Angel and. Participate in the SVB Securities Virtual Global Biopharma Conference, Jinshan Chen General!